Analysis of the survival curves between the expression levels of SLC31A1 and cancer patient survival showed that lower SLC31A1 expression significantly increased overall survival compared with individuals with higher SLC31A1 expression in Adrenocortical carcinoma (ACC), Breast invasive carcinoma (BRCA), Brain Lower Grade Glioma (LGG), Mesothelioma (MESO), Skin Cutaneous Melanoma (SKCM) (Figure 2). Here, SLC31A1 is linked to cutaneous melanoma.